Servier Pharmaceuticals’ Post

Facing a glioma diagnosis can be challenging. Discover essential tools and resources at My Glioma Guide to support you through this journey: https://ow.ly/k53E50SyO1N

Learn more about how blood-based biomarkers (BBMs) can help confirm an Alzheimer’s disease (AD) diagnosis. Dung Trinh, MD, Chief Medical Officer at the Healthy Brain Clinic, gives an overview of BBMs and what this testing method may hold for the future of AD diagnosis in this collaborative video series with Biogen. U.S. HCPs, learn more: https://ow.ly/5FaE50T9KXe #AlzheimersDisease #earlyAD #EndALZ

qFibrosis uses AI to analyze liver biopsy images and provide quantitative measurements of fibrosis on a continuous scale, shedding more insights into disease severity in MASH and MAFLD. Learn more here: https://lnkd.in/ggcSfXCD

If you're looking to build an in vitro model for Huntington's Disease, we can supply you with high-quality, functional striatal neurons. Let's have a conversation! Take a look below to see the striatal neurons chapter of our axoCells™ Catalog, or click here to download the full catalog: https://lnkd.in/epUnnZWt axoCells striatal neurons are assay-ready in just 31 days, and have been extensively characterized via immunohistochemistry to ensure they express key markers including DARPP32, CTIP2, CALBINDIN, GABA and MAP2. #iPSCs #StriatalNeurons #HuntingtonsDisease #HDModels #StemCells

📘 FREE Glioblastoma Educational Booklet 📘 Need trusted information on GBM? Our free booklet offers clear, easy-to-understand insights into diagnosis, treatment options, and support resources for patients and families. 💙 **PLEASE SHARE** 👉https://ow.ly/Y0A950TN9S4 #Glioblastoma #BrainTumorAwareness #BrainCancer #FreeResource

Research indicates that brain pathology leading to Alzheimer’s disease (AD) can begin up to two decades before symptoms appear. Now is the time to identify people at risk, who may benefit from earlier therapeutic intervention to slow or stop disease progression.     After many years of dedication to the AD community working to understand this complex disease, #MyCompany is leading where the AD research landscape is going, progressing the next generation of therapies in this space.     I’m energized by the immense potential of precision approaches to improve the care of targeted patient subpopulations at all stages of the disease. The future holds the potential to give the invaluable gift of time back to these patients, those at risk and their loved ones.    Watch this video for more on our work: https://bit.ly/4gxaEtD

At Envita, we’ve spent over two decades perfecting the art of personalized cancer care. 🧬 It’s all about targeting—going beyond generic treatments and delivering precision therapies that meet your body's unique needs. Here’s how we’re ahead of the game: ✅ Targeted medicines: Custom-made to hit the specific areas of the body that need healing. ✅ Data-driven care: Using advanced genetic testing, we create a "medical blueprint" for each patient. ✅ Immune modulation: Boosting your body’s defenses with personalized immune support. We are years ahead in personalized medicine and integrative care, helping our patients heal where traditional treatments have failed. 🔬🌱 Your health, your body, your recovery—designed just for YOU! 💪 #EnvitaMedical #PersonalizedMedicine #CancerTreatment #HealthInnovation #IntegrativeMedicine

As we mark #ParkinsonsAwarenessMonth, we are proud to share significant progress in our a-synuclein PET tracer program, bringing us closer to an imaging agent for the diagnosis of Parkinson’s Disease. ACI-12589 has proven specific and selective for a-syn, enabling us to visualize a-syn pathology in humans for the first time—a game changer for diagnosing multiple system atrophy and a leap towards #PrecisionMedicine. As we continue this journey, we are further leveraging our Morphomer platform to develop an imaging agent specifically optimized for #ParkinsonsDisease. Promising candidates such as ACI-15916 effectively bind to both large and smaller a-synuclein aggregates – crucial for detecting toxic proteins associated with Parkinson’s. The next-generation #asyn-PET tracer for PD is a critical step towards understanding and treating these complex diseases, much like how Abeta-PET has propelled Alzheimer’s clinical development. We are paving new paths in PD & MSA research, bringing hope to those affected by Parkinson's and MSA. For more details on our efforts to deliver the first PD tracer, watch Francesca Capotosti’s full presentation here: https://lnkd.in/gr6T5qK8 #ParkinsonsAwareness #NeurodegenerativeDiseases 

At Envita, we’ve spent over two decades perfecting the art of personalized cancer care. 🧬 It’s all about targeting—going beyond generic treatments and delivering precision therapies that meet your body's unique needs. Here’s how we’re ahead of the game: ✅ Targeted medicines: Custom-made to hit the specific areas of the body that need healing. ✅ Data-driven care: Using advanced genetic testing, we create a "medical blueprint" for each patient. ✅ Immune modulation: Boosting your body’s defenses with personalized immune support. We are years ahead in personalized medicine and integrative care, helping our patients heal where traditional treatments have failed. 🔬🌱 Your health, your body, your recovery—designed just for YOU! 💪 #EnvitaMedical #PersonalizedMedicine #CancerTreatment #HealthInnovation #IntegrativeMedicine

I have successfully developed and implemented a Logistic Regression model for the classification of breast tumors as either benign or malignant, achieving an accuracy of 96.5%. I encourage you to explore the possibilities of machine learning in healthcare for the early diagnosis for diseases, ultimately contributing to the fast treatment of patients. #machinelearning #ML #breastcancer #machinelearningmodel #machinelearningalgorithms #MLforhealthcare